<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047488</url>
  </required_header>
  <id_info>
    <org_study_id>tcapgbcomb1</org_study_id>
    <secondary_id>2009-013642-80</secondary_id>
    <nct_id>NCT01047488</nct_id>
  </id_info>
  <brief_title>Imipramine and Pregabalin Combination in Painful Polyneuropathy</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyneuropathy of different etiologies is often associated with pain and the standard
      treatment for this type of pain is gabapentinoids or antidepressants. The hypothesis of this
      study is that the combination of the gabapentinoid pregabalin and the antidepressant
      imipramine will provide better pain relief than the single compounds alone.

      This is a randomized, placebo-controlled, double-blind, 4-way, cross-over trial of pregabalin
      300 mg/day, imipramine 75 mg/day and their combination versus placebo. The study will include
      60 patients and the treatment outcome will be pain intensity as measured by numeric rating
      scales.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total pain intensity as measured by numeric rating scale 0-10 points.</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal pain relief scale with 6 classes</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific pain symptom rated by numeric rating scales 0-10 points</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of evoked pains symptoms (pressure, brush, repetitive pin-prick, cold) as measured by numeric rating scales 0-10 points</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep disturbance as measured by numeric rating scale 0-10 points</measure>
    <time_frame>Median of ratings from last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of escape medication (number of tablets of paracetamol)</measure>
    <time_frame>Total consumption during last week of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (SF-36)</measure>
    <time_frame>End of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory (MDI)</measure>
    <time_frame>End of each treament period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Imipramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipramine tablets and placebo capsules to pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin capsules and placebo tablets to imipramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipramine plus pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipramine tablets and pregabalin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets to imipramine and placebo capsules to pregabalin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks</description>
    <arm_group_label>Imipramine</arm_group_label>
    <other_name>Imipramin DAK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine, pregabalin</intervention_name>
    <description>Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks</description>
    <arm_group_label>Imipramine plus pregabalin</arm_group_label>
    <other_name>Imipramin DAK</other_name>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 - 85 years.

          -  Characteristic symptoms of polyneuropathy for at least 6 months.

          -  Polyneuropathy diagnosis confirmed by typical clinical signs (distal sensory
             disturbance/lack of distal deep tendon reflexes) and/or electrophysiological tests
             and/or abnormal quantitative sensory tests.

          -  Total pain intensity rating of at least 4 on a 0-10 points numeric rating scale.

          -  Pain present at least 4 days a week.

          -  For diabetics: diabetes diagnosis for at least 6 months and stable metabolic control
             for at least 3 months.

          -  For other secondary polyneuropathies: stable for at least 6 months.

          -  For fertile females: adequate anticonceptive treatment.

          -  Written informed consent.

        Exclusion Criteria:

          -  Other cause of pain.

          -  Contraindications against imipramine.

          -  Allergic reactions towards imipramine or pregabalin.

          -  Known adverse reactions during imipramine or pregabalin treatment.

          -  Pregnancy.

          -  Severe systemic disease.

          -  Ongoing treatment with antidepressants, antipsychotics, anticonvulsants, opioids,
             propranolol, kinidine, monoamine oxidase inhibitor.

          -  Inability to follow study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren H. Sindrup, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jakob V. Holbech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Søren H. Sindrup, MD</last_name>
    <phone>+45 65412471</phone>
    <email>soeren.sindrup@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob V. Holbech, MD</last_name>
    <email>Holbech@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flemming W. Bach, MD</last_name>
      <phone>+45 99321928</phone>
      <email>fwb@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Flemming W. Bach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren H. Sindrup, MD</last_name>
      <phone>+45 65412471</phone>
      <email>soeren.sindrup@ouh.regionsyddanmark.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jakob V. Holbech, MD</last_name>
      <email>Holbech@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Søren H. Sindrup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob V. Holbech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Troels S. Jensen, MD</last_name>
      <phone>+45 89494137</phone>
      <email>tsjensen@ki.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nanna Finnerup, MD</last_name>
      <email>finnerup@ki.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Troels S. Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanna Finnerup, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Søren Hein Sindrup</name_title>
    <organization>Department of Neurology, Odense University Hospital</organization>
  </responsible_party>
  <keyword>polyneuropathy</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

